AI medical stock landing MASSIVE contracts

It went up as much as 18,000% in two decades. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­

Dear Reader,

Few people know its name, but Intuitive Surgical was one of the five best stocks of the last 20 years.

It went up as much as 18,000% in two decades.

Why?

Because it used new technology - surgical robotics - to drive sales sky high.

Now... another company is following its path.

The company is tiny today - just $500 million - but it is in position to grow dramatically.

In short, it is the inventor of the world's first AI-designed drug to enter clinical trials.

And big pharma is lining up to use its patent-protected technology.

• Merck is collaborating with them on three projects that could generate up to $674 million in revenue.
• French pharma giant Sanofi agreed to pay the company up to $5.2 billion to develop 15 new drugs.
• Bristol Meyers Squibb signed a $1.2 billion partnership with the company.

You can see... each one of these projects is worth more than the entire market cap of this new AI stock!

In short, the upside is MASSIVE.

Which is why I wanted to send you this video.



It comes from one of the great stock pickers of all-time - a man who actually recommended Intuitive Surgical in real time back in 2004.

In fact, he called 4 of the top 6 performing stocks from 2000 to 2020.

And he says this new company is the #1 AI Stock Under $10.

Watch his free video breaking down the situation here.

Sincerely,

Rachel Gearhart
Associate Publisher, The Oxford Club
 
 

Thank you for subscribing to Insider Trades Daily, which covers the most recent insider buying and selling activity from Wall Street CEO's, CFO's, COO's and other insiders.
 
This message is a paid advertisement sent on behalf of The Oxford Club, a third-party advertiser of InsiderTrades.com and MarketBeat.
 
If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.
 
If you no longer wish to receive email from InsiderTrades.com, you can unsubscribe.
 
© 2006-2024 MarketBeat Media, LLC.
345 N Reid Place, Suite 620, Sioux Falls, SD 57103. United States.

 

Today's Bonus Content: The World's First "$20 Trillion Drug"?